Bioresorbable Coronary Stents Market To Reach $442.9 Million By 2030

Bioresorbable Coronary Stents Market Growth & Trends

The global bioresorbable coronary stents market size is expected to reach USD 442.9 million by 2030, expanding at a CAGR of 15.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. better device attributes of second-generation coronary stents will provide the ascending push to this market.

Bioresorbable stents are intended majorly for the young adult population, whereby these individuals are enabled with a normal functioning artery following complete resorption of the dissolvable devices.Lifestyle diseases and prevalence of associated risk factors underpin the growth in atherosclerosis-related cardiac events. This drives the global disease prevalence in young adults as well as the high volume of elective Percutaneous Coronary Interventions (PCI).

What sets the second-generation bioresorbable coronary stents apart? - Learning from past mistakes, manufacturers have developed new generation bioresorbable with thinner strut thicknesses, faster resorption times, and better radial force. Amaranth, with a single-minded focus on strut thickness, has developed three such devices. Each with a thinner strut. The latest, Magnitude boasts of 100 microns.

Another factor providing a fillip to this market is the less-invasive nature of PCIs as compared to coronary artery bypass grafting, resulting in their high elective procedure volume. In most parts of the world, lack of auditing to check inappropriate surgeries drives the number of coronary stenting procedures. Hence, this market is expected to witness growth due to the high volume of elective PCI, particularly in APAC and Europe.

 Request a free sample copy or view report summary: Bioresorbable Coronary Stents Market Report 

Bioresorbable Coronary Stents Market Report Highlights

• Asia Pacific is anticipated to register the fastest CAGR of 16.8% over the forecast period.

• Absorb BVS, among the key brands, engendered the highest sales revenue in 2022, while Absorb 2nd generation device will supersede the sales of its rival devices toward the end of the forecast period.

• The U.S. trails behind with low prominence in this market. The downfall of Abbott’s Absorb BVS, coupled with a lack of other bioresorbable stents seeking FDA clearance to capitalize on the opportunity, has resulted in low immediate prospects for bioresorbable coronary stents in this region

• Key players in this space include BIOTRONIK, Meril Lifesciences Pvt. Ltd., Abbott, Elixir Medical Corporation, REVA Medical, Arterial Remodeling Technologies, and Amaranth Medical

• Strategic efforts undertaken by the companies to gain a higher market share center on bioresorbable coronary stents development. Companies targeting the clinical pipeline have developed second-generation bioresorbable products with better design specifications, such as devices with thinner strut thicknesses and faster absorption rates that gain comparability with the gold standard, drug-eluting metallic stents.

Bioresorbable Coronary Stents Market Segmentation

Grand View Research has segmented the global bioresorbable coronary stents market based on brands, and region:

Bioresorbable Coronary Stents Brand Outlook (Revenue, USD Million, 2018 - 2030)

• Magmaris

• Magnitude

• MeRes100

• DESolve

• Others

Bioresorbable Coronary Stents Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Bioresorbable Coronary Stents Market

• Boston Scientific Corporation

• Medtronic

• Cordis

• Biotronik

• Meril Life Sciences Pvt. Ltd.

• Abbott

• Elixir Medical

• REVA Medical, LLC

• Arterial Remodeling Technologies SA